NL-OMON30949已完成不适用
A double blind randomized study on the effectiveness of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in dark irided hypermetropic children - effectiveness of cycloplegics
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 11（—）
入选标准
- •Healthy; not suffering from syndromes or diseases, 3 to 6 years (not attending group three of Dutch primary school system) old very dark irided hypermetropic children, possesing good accommodation, with no glasses prior or who did not wear their hypermetropic glasses since at least 4 weeks and able to fixate with each eye.
排除标准
- •All children not possesing the inclusioncriteria (D4a)
研究者
相似试验
进行中（未招募）
不适用
a double blind randomized study on the effectiveness of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in dark irided hypermetropic children - effectiveness of cycloplegicsrefraction of the eye/ refractive state of the eyeMedDRA version: 9.1Level: LLTClassification code 10038264Term: Refraction disorderEUCTR2007-003483-22-NLMedisch Centrum Haaglanden45
进行中（未招募）
不适用
A double blind randomized study on the efficacy of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in children - Efficacy of cycloplegicsDepth of cycloplegiachanges of astigmatismrecuperation from cycloplegia and mydriasisMedDRA version: 12.1Level: LLTClassification code 10011719Term: CycloplegiaMedDRA version: 12.1Level: PTClassification code 10011719Term: CycloplegiaEUCTR2010-021410-34-NLMedical Centre Haaglanden423
已完成
3 期
A double blind randomized study on the efficacy of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in childreNL-OMON34025Medisch Centrum Haaglanden419
进行中（未招募）
1 期
Efficacy and Safety of REGN727 added-on to Rosuvastatin versus Ezetimibe added-on to Rosuvastatin versus Rosuvastatin dose increase in patients who are not controlled on RosuvastatiPatients with Non-familial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) at high CV risk who are not adequately controlled with rosuvastatin (10mg or 20mg) with or without other lipid-modifying therapy (LMT) (excluding EZE)MedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-002333-11-ESRegeneron Pharmaceuticals, Inc.305
进行中（未招募）
不适用
Efficacy and Safety of REGN727/SAR236553 added-on to Atorvastatin versus Ezetimibe added-on to Atorvastatin versus Atorvastatin dose increase versus switch to Rosuvastatin in patients who are not controlled on AtorvastatiEUCTR2012-002344-24-DERegeneron Pharmaceuticals, Inc.420